Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis

Luke Bamber, Maria Y. Wang, Martin H. Prins, Cathleen Ciniglio, Rupert Bauersachs, Anthonie W. A. Lensing, Stefan J. Cano*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. This study evaluated patient-reported treatment satisfaction in EINSTEIN DVT - a large, open-label, randomised study that compared rivaroxaban with enoxaparin/vitamin K antagonist (VKA) therapy in patients with acute symptomatic DVT without PE. As part of EINSTEIN DVT a total of 1,472 patients in seven countries were asked to complete a new, validated measure of treatment satisfaction - the Anti-Clot Treatment Scale (ACTS) at scheduled visits throughout 12 months of treatment. ACTS scores were compared between study groups in the intention-to-treat population. Patients reported greater satisfaction in the rivaroxaban group compared with the enoxaparin/VKA group, with higher mean ACTS scores across visits. Mean ACTS Burdens scores were 55.2 vs 52.6 (p
Original languageEnglish
Pages (from-to)732-741
JournalThrombosis and Haemostasis
Issue number4
Publication statusPublished - Oct 2013


  • PRO instruments
  • rivaroxaban
  • treatment satisfaction
  • venous thromboembolism

Cite this